Sarcopenic obesity (SO; defined as obesity with low skeletal muscle function and mass) has been recently recognized as a relevant obesity phenotype, with substantial negative clinical impact. The prevalence of SO is likely increasing, due to the growing prevalence of...
Sarcopenia is characterized by age-related declines in muscle strength and mass, along with impaired physical function. It remains an unmet medical need, and there are no pharmacological interventions approved for this indication. The activation of growth hormone secretagogue receptor (GHSR)-1a,...
BACKGROUND
Exercise has been proposed as both a preventive and therapeutic countermeasure; however, its effectiveness across different disuse conditions and timings of implementation remains uncertain.
METHODS
This systematic review and meta-analysis (PROSPERO: CRD42021256599) searched ClinicalTrials.gov, Cochrane Central, PubMed, SPORTDiscus, Web of Science, Scopus,...
BACKGROUND
Diabetes mellitus-a chronic metabolic disorder associated with an increased risk of muscle atrophy-can significantly impact patients' quality of life and overall health outcomes. While antidiabetic medications are crucial for managing blood glucose levels, some have been linked to muscle-related adverse...
BACKGROUND
Sepsis-induced myopathy (SIM) is a severe complication that contributes to late-stage mortality and functional impairment in sepsis patients. The NLRP3 inflammasome plays a pivotal role in the pathogenesis of SIM, and its selective inhibitor MCC950 has shown promising therapeutic potential....
Sarcopenia and pain are two highly prevalent conditions in aging populations, each exerting profound effects on mobility, independence, and quality of life. Emerging evidence demonstrates that these conditions are not merely coincidental but are closely interconnected through shared biological, mechanical,...
BACKGROUND
Osteosarcopenia-the coexistence of osteopenia/osteoporosis and sarcopenia-is associated with numerous adverse health outcomes, but its association with intrinsic capacity (IC) remains unknown. We aimed to explore the associations of osteosarcopenia with IC and all-cause mortality in older adults.
METHODS
We conducted a cross-sectional...
BACKGROUND
Despite ongoing interest in anabolic therapies for sarcopenia and cachexia, pharmacological interventions are being developed to counteract age- and condition-related losses of muscle mass and strength. This systematic review and meta-analysis evaluated the effect of nandrolone decanoate on lean soft...
PURPOSE
Sarcopenia has already been widely investigated as a potential indicator of negative outcomes in oncology patients. Our aim was to evaluate the potential predictive role of sarcopenia assessed using an Artificial Intelligence-powered software in response to neoadjuvant chemotherapy (NAC) in...
PURPOSE
This preliminary study evaluated effect sizes of differences in circulating cell-free DNA (cfDNA) levels in blood and urine between older adults with and without sarcopenia.
METHODS
This was a subanalysis of the 2021 Itabashi Longitudinal Study on Aging. Twenty-four participants were selected...
BACKGROUND
Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder caused by mutations in the TAFAZZIN gene, which disrupts cardiolipin (CL) remodelling and mitochondrial function. While cardiac manifestations of BTHS are well characterized in male patients, the mechanisms underlying skeletal muscle...
Cancer cachexia, characterized by severe body weight loss, negatively affects patient quality of life and survival. Although moderate exercise benefits healthy and chronically ill individuals, and the effect of exercise in cachexia generally appears beneficial, conflicting results have been reported...
